Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

lenalidomide krka (previously lenalidomide krka d.d. novo mesto)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - imunosupresiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 a 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

LENALIDOMID TEVA 10MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid teva 10mg tvrdá tobolka

teva b.v., haarlem array - 21458 monohydrÁt lenalidomid-hydrochloridu - tvrdá tobolka - 10mg - lenalidomid

LENALIDOMID TEVA 15MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid teva 15mg tvrdá tobolka

teva b.v., haarlem array - 21458 monohydrÁt lenalidomid-hydrochloridu - tvrdá tobolka - 15mg - lenalidomid

LENALIDOMID TEVA 25MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid teva 25mg tvrdá tobolka

teva b.v., haarlem array - 21458 monohydrÁt lenalidomid-hydrochloridu - tvrdá tobolka - 25mg - lenalidomid

LENALIDOMID TEVA 5MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomid teva 5mg tvrdá tobolka

teva b.v., haarlem array - 21458 monohydrÁt lenalidomid-hydrochloridu - tvrdá tobolka - 5mg - lenalidomid

Lenalidomide Krka d.d. Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

lenalidomide krka d.d.

krka, d.d., novo mesto  - lenalidomide hydrochloride hydrate - multiple myeloma; lymphoma, follicular; myelodysplastic syndromes - imunosupresiva - multiple myelomalenalidomide krka d. as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) je indikován k léčbě dospělých pacientů s dříve neléčeným mnohočetným myelomem, kteří nejsou způsobilí pro transplantaci. lenalidomide krka d. in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka d. as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. follicular lymphomalenalidomide krka d. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Lenalidomide Mylan Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

lenalidomide mylan

mylan ireland limited - lenalidomid - mnohočetný myelom - imunosupresiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).

LENALIDOMIDE GRINDEKS 10MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomide grindeks 10mg tvrdá tobolka

as grindeks, riga array - 3207 lenalidomid s chloridem amonnÝm - tvrdá tobolka - 10mg - lenalidomid

LENALIDOMIDE GRINDEKS 15MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomide grindeks 15mg tvrdá tobolka

as grindeks, riga array - 3207 lenalidomid s chloridem amonnÝm - tvrdá tobolka - 15mg - lenalidomid

LENALIDOMIDE GRINDEKS 20MG Tvrdá tobolka Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

lenalidomide grindeks 20mg tvrdá tobolka

as grindeks, riga array - 3207 lenalidomid s chloridem amonnÝm - tvrdá tobolka - 20mg - lenalidomid